How do you approach EGFR mutated NSCLC with isolated progression in the chest who is planned for a course of radiation at least 3-4 weeks?   

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

Answer from: Medical Oncologist at Academic Institution
Radiation Oncologist at USC Keck School of Medicine
Thank you Dr. @Gregory A. Otterson for this c...
Sign in or Register to read more